Skip to content
You are now leaving https://www.ionispharma.com to visit

Ionis and Akcea Partner to Commercialize Inotersen for hATTR

Ionis licenses to Akcea worldwide rights to inotersen and IONIS-TTR-L Rx Collaboration advances commercial readiness for planned mid-2018 inotersen launch, positioning Akcea to successfully launch two drugs for significant rare diseases this year Ionis Chief Business Officer Sarah Boyce will join